Atossa Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Atossa Therapeutics, Inc. (ATOS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-25.50-30.09-26.96-20.61-17.83-17.24-11.40
Depreciation & Amortization0.020.020.010.020.050.050.04
Stock Based Compensation2.294.626.795.273.020.000.00
Change in Working Capital0.451.52-0.60-1.16-0.11-0.53-0.06
Change in Inventory-0.610.000.000.000.000.000.00
Change in Accounts Payable-0.13-2.161.250.131.300.000.00
Change in Other Working Capital0.583.68-1.85-1.28-1.410.000.00
Other Operating Activities1.720.007.124.833.308.620.00
Net Cash from Operating Activities-21.03-20.94-20.76-16.47-11.57-9.13-8.96
Investing Activities
Capital Expenditures-0.02-0.01-0.03-0.01-0.010.01-0.11
Purchases of Investments0.000.00-4.700.000.000.000.00
Sales/Maturities of Investments0.000.00-4.700.000.000.000.00
Other Investing Activities0.000.00-4.700.000.000.000.00
Net Cash from Investing Activities-0.02-0.01-4.73-0.01-0.01-0.01-0.11
Financing Activities
Common Stock Issued3.670.000.0069.6733.620.0012.29
Common Stock Repurchased0.00-1.480.00-0.57-0.010.000.00
Other Financing Activities0.000.000.00-0.570.000.000.00
Net Cash from Financing Activities3.67-1.480.00113.3038.5511.3412.29
Summary
Net Change in Cash-17.38-22.43-25.4996.8226.972.203.22
Cash at Beginning of Period88.57111.00136.4939.660.0010.497.27
Cash at End of Period71.1988.57111.00136.490.0012.6910.49
Free Cash Flow-21.05-20.96-20.79-16.48-11.58-9.14-9.07